These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35345474)

  • 1. Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety.
    Qu J; Qi TT; Qu Q; Long WM; Chen Y; Luo Y; Wang Y
    Infect Drug Resist; 2022; 15():1205-1218. PubMed ID: 35345474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections.
    Lu Q; Zhu HH; Li GH; Qi TT; Ye LJ; Teng XQ; Qu Q; He GF; Qu J
    Front Med (Lausanne); 2021; 8():620885. PubMed ID: 33634151
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
    Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
    J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study.
    Zhang X; Qi S; Duan X; Han B; Zhang S; Liu S; Wang H; Zhang H; Sun T
    J Transl Med; 2021 Oct; 19(1):431. PubMed ID: 34656132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China.
    Li L; Huang X; Liu J; Li C; Lin Z; Ren R; Zhang Y; Ding H; Chen J; Mao Y
    Infect Drug Resist; 2024; 17():3057-3071. PubMed ID: 39050834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study.
    Cai Y; Leck H; Tan RW; Teo JQ; Lim TP; Lee W; Chlebicki MP; Kwa AL
    Antibiotics (Basel); 2020 Jul; 9(8):. PubMed ID: 32726974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB.
    Liu D; Jie F; Ding Y; Qu H; Chen D; Huang J
    J Infect Dev Ctries; 2024 Jul; 18(7):1050-1057. PubMed ID: 39078788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.
    Wu X; Huang C; Wang H; Ji J; Ying C; Xiao Y
    Drug Des Devel Ther; 2021; 15():2593-2603. PubMed ID: 34168431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections.
    Wu XL; Long WM; Lu Q; Teng XQ; Qi TT; Qu Q; He GF; Qu J
    Front Pharmacol; 2022; 13():672543. PubMed ID: 35571125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug-resistant gram-negative bacteria.
    Yu LL; Shi XP; Huang JF; Gong Y; Cui CX; Wang T
    J Clin Pharm Ther; 2022 Oct; 47(10):1563-1569. PubMed ID: 35670240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB.
    Wang J; Shah BK; Zhao J; Xiong J; Wang C; Xie S
    BMC Infect Dis; 2023 May; 23(1):351. PubMed ID: 37231342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Efficacy of Polymyxin B in Patients Infected with Carbapenem-Resistant Organisms.
    Lu Q; Li GH; Qu Q; Zhu HH; Luo Y; Yan H; Yuan HY; Qu J
    Infect Drug Resist; 2021; 14():1979-1988. PubMed ID: 34093026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity and Efficacy Assessment of Polymyxin B Use in Renal Transplant Patients.
    Wen YX; Qu Q; Long WM; Luo Y; Zhuang HH; Teng XQ; Qu J
    Infect Drug Resist; 2022; 15():275-283. PubMed ID: 35115795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial.
    Liu S; Wu Y; Qi S; Shao H; Feng M; Xing L; Liu H; Gao Y; Zhu Z; Zhang S; Du Y; Lu Y; Yang J; Chen P; Sun T
    Crit Care; 2023 Jun; 27(1):232. PubMed ID: 37312218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Influencing Factors of Polymyxin B in High-Level Carbapenem-Resistant
    Jia X; Yin Z; Zhang W; Du S
    Infect Drug Resist; 2023; 16():4177-4187. PubMed ID: 37396067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections.
    Simon V; Viswam A; Alexander PS; James E; Sudhindran S
    Indian J Pharmacol; 2023; 55(4):229-236. PubMed ID: 37737075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and nephrotoxicity of intravenous colistin sulfate in the treatment of carbapenem-resistant gram-negative bacterial infections: a retrospective cohort study.
    Jin J; Zhu J; Zhu Z; Kim WY; O'Rourke J; Lin Z; Chen M
    Ann Transl Med; 2022 Oct; 10(20):1137. PubMed ID: 36388829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections.
    Xia GL; Jiang RL
    BMC Infect Dis; 2021 Oct; 21(1):1034. PubMed ID: 34607561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study.
    Wu Z; Zhang S; Cao Y; Wang Q; Sun K; Zheng X
    Front Pharmacol; 2023; 14():1209063. PubMed ID: 37663252
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical analysis of sepsis with extensively drug resistant Gram-negative bacteria in intensive care unit treated with polymyxin B-based combination therapy].
    Zhao S; Yan L; Wang C; Peng M
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Feb; 32(2):150-154. PubMed ID: 32274997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.